When patients were grouped according to UCP2 expression in carcinoma tissues, NSCLC patients with high UCP2 expression levels had longer progression-free survival (PFS) than those with low UCP2 expression (Figure 2C). Here, UCP2 is linked to non-small cell lung carcinoma.